No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis

Clinical Rheumatology

Volumn 28, Issue 7, 2009, Pages 825-833

  Hettema, Martha E ^a   Zhang, Dan ^a   Stienstra, Ymkje ^a   Smit, Andries J ^a   Bootsma, Hendrika ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bosentan; Endothelial cell dysfunction; Raynaud's phenomenon; Systemic sclerosis

Indexed keywords

ACETYLCHOLINE; BOSENTAN; FLUORESCEIN SODIUM; NITROPRUSSIDE SODIUM; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CAPILLARY PERMEABILITY; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE MICROSCOPY; FOLLOW UP; HUMAN; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SEROLOGY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; VASODILATATION; VIDEODENSITOMETRY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LASER-DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; NAILS; OUTPATIENTS; PILOT PROJECTS; RAYNAUD DISEASE; REGIONAL BLOOD FLOW; SCLERODERMA, LIMITED; SULFONAMIDES; TREATMENT OUTCOME; VASODILATION;

EID: 67349179460     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1157-4     Document Type: Article

References (52)

1. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA et al (1988) Scleroderma (systemic-sclerosis) - classification, subsets and pathogenesis. J Rheumatol 15:202-205
2. Wigley FM (2002) Clinical practice. Raynaud's phenomenon. N Engl J Med 347:1001-1008
3. Bollinger A, Jager K, Siegenthaler W (1986) Microangiopathy of progressive systemic sclerosis. Evaluation by dynamic fluorescence videomicroscopy. Arch Intern Med 146:1541-1545
4. Grassi W, Core P, Carlino G, Cervini C (1994) Effects of peripheral cold exposure on microvascular dynamics in systemic sclerosis. Arthritis Rheum 37:384-390
5. Anderson ME, Campbell F, Hollis S, Moore T, Jayson MI, Herrick AL (1999) Non-invasive assessment of digital vascular reactivity in patients with primary Raynaud's phenonenon and systemic sclerosis. Clin Exp Rheumatol 17:49-54
6. Generini S, Kahaleh B, Matucci-Cerinic M, Pignone A, Lombardi A, Ohtsuka T (1996) Raynaud's phenomenon and systemic sclerosis. Ann Ital Med Int 11:125-131
7. Kahaleh B, Matucci-Cerinic M (1995) Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 38:1-4
8. Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L et al (2000) Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: Findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 43:1085-1093
9. Cerinic MM, Valentini G, Sorano GG, D'Angelo S, Cuomo G, Fenu L et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285-295
10. Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM et al (1995) Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 34:1048-1054
11. Gruschwitz MS, Hornstein OP, von Den DP (1995) Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 38:184-189
12. Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI (1996) Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 55:122-127
13. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K (1998) Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 37:1188-1192
14. Ferri C, Latorraca A, Catapano G, Greco F, Mazzoni A, Clerico A et al (1993) Increased plasma endothelin-1 immunoreactive levels in vasculitis: A clue to the use of endothelin-1 as a marker of vascular damage? J Hypertens Suppl 11(Suppl 5):S142-S143
15. Filep JG, Bodolay E, Sipka S, Gyimesi E, Csipo I, Szegedi G (1995) Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective-tissue disease. Circulation 92:2969-2974
16. Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo AM, Fyhrquist F (1991) Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis 50:526-527
17. Kahaleh MB (1991) Endothelin, an endothelial-dependent vasoconstrictor in scleroderma - enhanced production and profibrotic action. Arthritis Rheum 34:978-983
18. Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V et al (1995) Plasma endothelin-1 levels, pulmonary-hypertension, and lung fibrosis in patients with systemic-sclerosis. Am J Med 99:255-260
19. Yamane K, Kashiwagi H, Suzuki N, Miyauchi T, Yanagisawa M, Goto K et al (1991) Elevated plasma-levels of endothelin-1 in systemic-sclerosis. Arthritis Rheum 34:243-244
20. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985-3993
21. Hettema ME, Zhang D, Bootsma H, Kallenberg CGM (2007) Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 66:1398-1399
22. Wouda AA (1977) Raynaud's phenomenon. Photoelectric plethysmography of the fingers of persons with and without Raynaud's phenomenon during cooling and warming up. Acta Med Scand 201:519-523
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic-sclerosis (scleroderma). Arthritis Rheum 23:581-590
24. Blaauw J, Graaff R, van Pampus MG, van Doormaal JJ, Smit AJ, Rakhorst G et al (2005) Abnormal endothelium-dependent microvascular reactivity in recently preeclamptic women. Obstet Gynecol 105:626-632
25. Cracowski JL, Carpentier PH, Imbert B, Cachot S, Stanke-Labesque F, Bessard J et al (2002) Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: Effect of cold exposure. Arthritis Rheum 46:1319-1323
26. Serne EH, Gans ROB, ter Maaten JC, ter Wee PM, Donker AM, Stehouwer CDA (2001) Capillary recruitment is impaired in essential hypertension and relates to insulin's metabolic and vascular actions. Cardiovasc Res 49:161-168
27. Morris SJ, Shore AC, Tooke JE (1995) Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 38:1337-1344
28. de Jongh RT, Serne EH, Ijzerman RG, de Vries G, Stehouwer CD (2004) Impaired microvascular function in obesity: Implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 109:2529-2535
29. Serne EH, Stehouwer CD, ter Maaten JC, ter Wee PM, Rauwerda JA, Donker AJ et al (1999) Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 99:896-902
30. Jager J, Oomen PH, Sluiter WJ, Reitsma WD, Smit AJ (1997) Improved reproducibility of the 'large-window' method of assessing transcapillary and interstitial fluorescein diffusion in the skin in healthy subjects and in subjects with insulin-dependent diabetes mellitus. Int J Microcirc Clin Exp 17:150-158
31. Oomen PH, Jager J, Hoogenberg K, Dullaart RP, Reitsma WD, Smit AJ (1999) Capillary permeability is increased in normo- and microalbuminuric type 1 diabetic patients: Amelioration by ACE-inhibition. Eur J Clin Invest 29:1035-1040
32. Houtman PM. Microvascular and immunological studies in Raynaud's phenomenon. Academic thesis Groningen, the Netherlands 1985
33. De Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M (2005) Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 64:753-759
34. Fagrell B (1995) Advances in microcirculation network evaluation: An update. Int J Microcirc Clin Exp 15(Suppl 1):34-40
35. Wright CI, Kroner CI, Draijer R (2006) Non-invasive methods and stimuli for evaluating the skin's microcirculation. J Pharmacol Toxicol Methods 54:1-25
36. Farkas K, Kolossvary E, Jarai Z, Nemcsik J, Farsang C (2004) Non-invasive assessment of microvascular endothelial function by laser Doppler flowmetry in patients with essential hypertension. Atherosclerosis 173:97-102
37. Ijzerman RG, de Jongh RT, Beijk MA, van Weissenbruch MM, Delemarre-van de Waal HA, Serne EH et al (2003) Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur J Clin Invest 33:536-542
38. Khan F, Elhadd TA, Greene SA, Belch JJ (2000) Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care 23:215-220
39. La Civita L, Rossi M, Vagheggini G, Storino FA, Credidio L, Pasero G et al (1998) Microvascular involvement in systemic sclerosis: Laser Doppler evaluation of reactivity to acetylcholine and sodium nitroprusside by iontophoresis. Ann Rheum Dis 57:52-55
40. Marasini B, Conciato L (2001) Iontophoretic evaluation of vascular reactivity to acetylcholine in patients with primary Raynaud's phenomenon and systemic sclerosis. Clin Rheumatol 20:451-452
41. Anderson ME, Hollis S, Moore T, Jayson MI, Herrick AL (1996) Non-invasive assessment of vascular reactivity in forearm skin of patients with primary Raynaud's phenomenon and systemic sclerosis. Br J Rheumatol 35:1281-1288
42. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P et al (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56:1985-1993
43. Gori T, Di SG, Sicuro S, Dragoni S, Lisi M, Parker JD et al (2006) Correlation analysis between different parameters of conduit artery and microvascular vasodilation. Clin Hemorheol Microcirc 35:509-515
44. Hansell J, Henareh L, Agewall S, Norman M (2004) Non-invasive assessment of endothelial function - relation between vasodilatory responses in skin microcirculation and brachial artery. Clin Physiol Funct Imaging 24:317-322
45. Dick EA, Aviv R, Francis I, Hamilton G, Baker D, Black C et al (2001) Catheter angiography and angioplasty in patients with scleroderma. Br J Radiol 74:1091-1096
46. Stucker M, Quinna S, Memmel U, Rochling A, Traupe M, Hoffmann K et al (2000) Macroangiopathy of the upper extremities in progressive systemic sclerosis. Eur J Med Res 5:295-302
47. Moore TL, Vail A, Herrick AL (2007) Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology (Oxford) 46:363-364
48. Baer-Suryadinata C, Bollinger A (1985) Transcapillary diffusion of Na-fluorescein measured by a 'large window technique' in skin areas of the forefoot. Int J Microcirc Clin Exp 4:217-228
49. Oomen PH, Kant GD, Dullaart RP, Tervaert JW, Reitsma WD, Smit AJ (2004) No effects of acute hyperglycaemia and hyperinsulinaemia on skin microcirculation and endothelial markers in Type II diabetes mellitus. Scand J Clin Lab Invest 64:119-127
50. Kahaleh MB, Osborn I, Leroy EC (1981) Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 94:482-484
51. Matsuda J, Tsukamoto M, Gohchi K, Saitoh N, Miyajima Y, Kazama M (1992) Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon. Acta Haematol 88:189-193
52. Brevetti G, De Caterina M, Martone VD, Corrado S, Silvestro A, Spadaro G et al (2000) Measurement of soluble adhesion molecules in primary Raynaud's phenomenon and in Raynaud's phenomenon secondary to connective tissue diseases. Int J Clin Lab Res 30:75-81